Evidence map›Paper›PMID 35739237›Full record

ArticleCell research2022

A SNIPpet of safety: a Goldilocks approach in CAR-T therapy.

Mehdi Benzaoui, Naomi Taylor, Nirali N Shah

Abstract readComment
In one paragraph

Article in Cell research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Validation and analysis of 12,000 AI-driven CAR-T designs in thebioRxiv : the preprint server for biology · 2026
    Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Mehdi BenzaouiPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0003-4453-367X
Naomi TaylorPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. taylorn4@mail.nih.gov.ORCID 0000-0002-2459-4558
Nirali N ShahPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. nirali.shah@mail.nih.gov.ORCID 0000-0002-8474-9080

Funding

Metabolic regulation of T cell effector function and anti-tumor immunotherapyZIABC011923 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI TAYLOR, NAOMI · 2019 to 2025
$9.5M
Immunotherapeutic approaches to treat pediatric hematologic malignanciesZIABC011823 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI SHAH, NIRALI · 2019 to 2025
$6.1M
Development of Novel Immunotherapeutic Strategies for Myeloid MalignanciesZIABC011927 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI SHAH, NIRALI · 2019 to 2025
$3.5M
Intramural NIH HHS ZIA BC011923Intramural NIH HHS ZIA BC011927
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Immunotherapy, AdoptiveReceptors, Chimeric AntigenReceptors, Chimeric Antigen

Identifiers

PMID35739237
PMCPMC9253012

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.